Amin Fawzi, Al Hajeri Amani, Civelek Birol, Fedorowicz Zbys, Manzer Bruce M
Ministry of Health Bahrain, Box 22118, Manama, Bahrain.
Cochrane Database Syst Rev. 2010 Feb 17;2010(2):CD007219. doi: 10.1002/14651858.CD007219.pub2.
Cardiovascular disease is a major cause of death in developed and developing countries. Refractory stable angina pectoris is, in general, inadequately responsive to conventional medical therapy.Enhanced external counterpulsation is a non-invasive treatment for patients with refractory angina and involves the placing of compressible cuffs around the calves and lower and upper thighs. These are inflated sequentially so that during early diastole they help propel blood back to the heart and when deflated at end of diastole allow the blood vessels to return to their normal state. It is claimed that enhanced external counterpulsation can help reduce aortic impedance and thereby alleviate some of the symptoms of angina.
To assess the effects of enhanced external counterpulsation therapy in improving health outcomes for patients with chronic stable or refractory stable angina pectoris.
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) on The Cochrane Library (2008, Issue 1), MEDLINE (1966 to February 2008), EMBASE (1980 to February 2008), LILACS via BIREME (to February 2008) and ISI Science Citation Index on Web of Science (to February 2008). No language restrictions were applied.
Randomized controlled trials and cluster-randomized trials comparing enhanced external counterpulsation therapy to sham treatment in adults, aged over 18 years, with chronic stable and stable refractory angina pectoris graded Canadian Cardiovascular Society Class III to IV at baseline.
Two authors independently screened papers, extracted trial details and assessed risk of bias.
One trial (139 participants) was included in this review. Poor methodological quality, in terms of trial design and conduct, incompleteness in reporting of the review's primary outcome, limited follow up for the secondary outcomes and subsequent flawed statistical analysis, compromised the reliability of the reported data.
AUTHORS' CONCLUSIONS: We found one relevant trial which failed to address the characteristics of interest satisfactorily, in terms of severity of angina, for the participants in this review. Participants with the most severe symptoms of angina were excluded, therefore the results of this study represent only a subsection of the broader population with the disorder, are not generalizable and provide inconclusive evidence for the effectiveness of enhanced external counterpulsation therapy for chronic angina pectoris.
心血管疾病是发达国家和发展中国家的主要死因。难治性稳定型心绞痛通常对传统药物治疗反应欠佳。增强型体外反搏是一种针对难治性心绞痛患者的非侵入性治疗方法,需要在小腿以及大腿上下部放置可压缩的袖带。这些袖带依次充气,以便在舒张早期帮助将血液推送回心脏,在舒张末期放气时使血管恢复正常状态。据称,增强型体外反搏有助于降低主动脉阻抗,从而缓解心绞痛的一些症状。
评估增强型体外反搏治疗对改善慢性稳定型或难治性稳定型心绞痛患者健康结局的效果。
我们检索了《考克兰系统评价数据库》(2008年第1期)中的考克兰对照试验中心注册库(CENTRAL)、MEDLINE(1966年至2008年2月)、EMBASE(1980年至2008年2月)、通过BIREME检索的拉丁美洲及加勒比地区卫生科学数据库(LILACS,至2008年2月)以及科学网(Web of Science)上的ISI科学引文索引(至2008年2月)。未设语言限制。
随机对照试验和整群随机试验,比较增强型体外反搏治疗与假治疗对年龄在18岁以上、基线时加拿大心血管学会分级为III至IV级的慢性稳定型和稳定型难治性心绞痛成年患者的疗效。
两位作者独立筛选论文、提取试验细节并评估偏倚风险。
本评价纳入了1项试验(139名参与者)。从试验设计和实施来看,方法学质量较差,综述主要结局报告不完整,次要结局随访有限,后续统计分析存在缺陷,这些都损害了所报告数据的可靠性。
我们发现1项相关试验,就心绞痛严重程度而言,未能令人满意地解决本综述中参与者的相关特征问题。心绞痛症状最严重的参与者被排除在外,因此本研究结果仅代表患有该疾病的更广泛人群中的一个子集,不具有普遍性,且为增强型体外反搏治疗慢性心绞痛的有效性提供了不确定的证据。